Eagle0, I would think that Jon Pilcher is talking about ensuring that patent applications are filed to protect any new indications rather than it being an issue of waiting for an existing patent application to be granted.
I note that the patent Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders (2013 priority date) specifically lists a number of neurodevelopmental disorders proposed to be treatable by NNZ-2591, including Rett syndrome, Fragile-X syndrome, Phelan McDermid syndrome and Angelman syndrome. Neither Pitt Hopkins syndrome nor Prader-Willi syndrome are specifically mentioned in this patent and notably, patent applications to cover each of these disorders have since been filed.
The patent Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders also specifically lists Tuberous Sclerosis Complex and CDKL5 mutations, both of which I included in my list of suggested possible further indications of NNZ-2591.
I suspect that other neurodevelopmental disorders not specified in the original patent will, like PHS and PWS, be covered by new patent applications with preclinical data to back up the claims.
Just my thinking and I could be wrong.
NEU Price at posting:
$12.90 Sentiment: Hold Disclosure: Held
(20min delay)